News
Media
Between the LinesExpert InterviewsK-CastMedical World NewsPodcastsPopulation Health Perspectives
Conferences
Partners
More
Publications
All PublicationsMHE PublicationFormulary Watch SupplementsFormulary Watch SpotlightsSupplements And Featured Publications
Events
Webinars
CME/CE
Resources
PBMI InnovatorsEmerging LeadersInteractive ToolsSponsored Content
PBM Directory

Subscribe

  • News
  • Media
  • Conferences
  • Partners
  • Publications
  • Events
  • CME/CE
  • Resources
  • PBM Directory
  • Subscribe
  • Asthma
  • Atrial Fibrillation
  • Autoimmune Diseases
  • Biologics
  • Biosimilars
  • Blood Cancer
  • Breast Cancer
  • COVID-19
  • Cardiovascular Diseases
  • Depression
  • Dermatology
  • Diabetes
  • Digital Health
  • Drug Coverage
  • Duchenne Muscular Dystrophy
  • Eyecare
  • FDA
  • Friedreich Ataxia
  • Gene Therapy
  • Graft Versus Host Disease
  • HIV
  • Health Systems
  • Heart Failure
  • Hemophilia
  • Hypertrophic Cardiomyopathy (HCM)
  • Infectious Disease
  • Leukemia and Lymphoma
  • Liver Disease
  • Lung Cancer
  • Mental Health
  • Multiple Sclerosis
  • NSCLC
  • Neonatal Care
  • Nephrology
  • Obstetrics-Gynecology & Women's Health
  • Oncology
  • Oncology Biomarkers
  • Opioids
  • PTSD
  • Pain
  • Pediatrics
  • Plaque Psoriasis
  • Population Health
  • Post-Acute Care
  • Prescription Digital Therapeutics
  • Pulmonary Arterial Hypertension
  • RSV
  • Reproductive Health
  • Respiratory Conditions
  • Safety & Recalls
  • Schizophrenia
  • Shingles
  • Skin Cancer
  • Sleep Disorders
  • Solid Tumors
  • Spinal Muscular Atrophy
  • Substance Use Disorder
  • The Improving Patient Access Podcast
  • Type I Diabetes
  • Type II Inflammation
  • Ulcerative Colitis
  • Uro-Oncology
  • Urothelial Carcinoma
  • Vaccines
  • Women's Health
Spotlight -
Nov 25 Cover Story: DTC Drug Sales|
AMCP Nexus 2025|
2025 Fall Clinical Dermatology|
ASRS 2025
Advertisement

Charles A. DeMonaco

Advertisement

Articles by Charles A. DeMonaco

DOJ Issues Important Updates to Evaluation of Corporate Compliance Guidance

ByOksana G. Wright,Charles A. DeMonaco,Jana Volante Walshak
July 28th 2020

A strong, up-to-date compliance program should be part of a healthcare company's risk management strategy.

Advertisement

Latest Updated Articles

  • DOJ Issues Important Updates to Evaluation of Corporate Compliance Guidance
    DOJ Issues Important Updates to Evaluation of Corporate Compliance Guidance

    Published: July 28th 2020 | Updated:



Advertisement
Advertisement

Trending on Managed Healthcare Executive

1

Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints

2

COVID-19 vaccines could help tumors respond better to immune checkpoint inhibitors

3

Keytruda shows survival edge over Tecentriq, Opdivo in older patients with lung cancer

4

FDA approves Poherdy, first biosimilar of Perjeta, to treat HER-positive breast cancer

5

Integrin beta-6 emerges as a novel biomarker for NSCLC

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Formulary Watch
  • Pharmacy Benefit Management Institute
Managed Healthcare Executive
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us